Which is better, BPC-157 or TB-500?
The two are tied on the things that matter most: both are graded animal only, both have the same regulatory status (not on the bulks list, covered only as single-ingredient products by HHS's draft enforcement discretion policy), and both are prohibited by WADA. BPC-157's animal data are more specific to tendon and gastrointestinal injury but come mostly from one research group; TB-500 is a 7 amino acid fragment of thymosin beta-4, and its own studies cover only how it is absorbed and broken down in horses and rats, plus a cell study in which it did not close scratch wounds. The independent skin wound and cardiac studies and the human eye drop trial used full-length thymosin beta-4, which FDA says is not the same substance, and TB-500 has not been tested that way. The honest answer is that no human evidence favors either; BPC-157 has animal healing data of its own and TB-500 does not, but that does not make either a proven choice, and HHS's draft policy does not change either evidence grade. [1] [2] [5] [7] [9] [10] [16] [17] [18] [20]
How do BPC-157 and TB-500 compare?
| Dimension | BPC-157 | TB-500 |
|---|---|---|
| What it is [4] [8] [16] | Synthetic 15 amino acid fragment of a gastric protein (body protection compound). Not found as such in the body. | Synthetic 7 amino acid fragment (acetylated LKKTETQ) of thymosin beta-4, a 43 amino acid actin binding protein present in nearly all human cells. FDA says thymosin beta-4 and TB-500 are not the same substance. |
| Proposed mechanism [1] [3] [6] [8] [16] | Upregulates growth factor receptor signaling, modulates the nitric oxide system, and promotes angiogenesis through VEGFR2 in animal and cell models. | Hypothesized, not shown, to share the actin binding role of thymosin beta-4. The mechanisms usually quoted (sequestering G-actin to support cell migration, activating the ILK and Akt survival pathway, reducing inflammation and scarring) were documented with full-length thymosin beta-4 in animal and cell models. |
| Strongest animal evidence [1] [4] [5] [6] [16] [17] [18] | Rat Achilles tendon transection: faster healing and more tendon fibroblast outgrowth, survival, and migration. Rodent gut studies report healing of NSAID ulcers, fistulas, and anastomoses. | No animal study has tested whether TB-500 heals wounds; its own studies tracked how it is broken down in horses and rats. The well-known results used full-length thymosin beta-4: rat full thickness wounds with reepithelialization up 42% at day 4 and up to 61% at day 7, and better cardiomyocyte survival and cardiac function in a mouse heart attack model. |
| Human evidence [2] [7] [13] [15] [16] | No controlled human trial. Three small uncontrolled pilot reports from one clinic (knee pain, interstitial cystitis, and intravenous safety) reported benefit or no adverse events but had no comparison group. | No human study of TB-500: FDA's July 2026 briefing found no article in which it was given to humans. The trials often cited used full-length thymosin beta-4: a phase 2 eye drop trial in 72 adults with dry eye missed both primary endpoints, and phase 1 intravenous studies in healthy volunteers found it well tolerated; neither tested injury healing. |
| Independence of the research base [2] [5] [6] [17] [18] | Most studies come from a small number of laboratories, mostly in Zagreb, with limited independent replication. | The wound and cardiac findings from several independent groups, including a Nature paper on cardiac repair, are for full-length thymosin beta-4. TB-500's own studies are a horse doping control study and a rat and cell metabolism study. |
| Routes in the literature [4] [5] [7] [15] [16] [17] | Rodent work used intraperitoneal injection, oral dosing in drinking water, and topical application; BPC-157 is reported to be active orally in animals. | TB-500 was given by subcutaneous injection in the horse study; no human route has been studied. The thymosin beta-4 rodent work used topical application and intraperitoneal injection, and its human trials used eye drops and intravenous infusion. |
| FDA and compounding status [9] [10] [20] [21] | Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. Covered by HHS's October 28, 2026 draft enforcement discretion policy: HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (subcutaneous, intramuscular, oral, or topical) on a patient-specific prescription, if sourcing, testing, and adverse event reporting conditions are met. The draft is not binding and may be revisited. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). | Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. Covered by HHS's October 28, 2026 draft enforcement discretion policy: HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (subcutaneous or intramuscular injection only) on a patient-specific prescription, if sourcing, testing, and adverse event reporting conditions are met. The draft is not binding and may be revisited. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). |
| Note: Same draft policy for both, with different allowed routes. Neither is on the 503A bulks list, and a blend of the two (often sold as Wolverine) is not covered because the policy is limited to single-ingredient products. | ||
| WADA status [11] [12] | Prohibited at all times under S0 (non-approved substances). | Prohibited at all times under S2; thymosin beta-4 and TB-500 are named on the list. |
| Typical cost [9] [19] [20] | No verified compounded price yet: HHS's draft enforcement discretion policy was only announced on October 28, 2026, and advertised clinic prices are not a comparable price. | No verified compounded price yet: HHS's draft enforcement discretion policy was only announced on October 28, 2026, and advertised clinic prices are not a comparable price. Often marketed alongside BPC-157, but blends of the two are not covered by the draft policy. |
| Note: Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. | ||
Evidence grade and regulatory status
Pulled from each peptide’s own record, so it stays in step with the peptide pages.
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Class | Synthetic gastric pentadecapeptide (15 amino acids), fragment of body protection compound | Synthetic N-acetylated 7 amino acid fragment (amino acids 17 to 23, LKKTETQ) of thymosin beta-4, a 43 amino acid actin sequestering protein |
| What it is | A 15 amino acid peptide with strong animal healing data, no randomized human trial in PubMed, and a draft HHS compounding policy from October 2026. | Synthetic 7 amino acid fragment of thymosin beta-4. No human study of TB-500 itself; the human trials used the full-length protein. WADA banned. |
| Evidence | Evidence: Animal-only evidence | Evidence: Animal-only evidence |
| FDA status | Regulatory: HHS interim policy (draft) | Regulatory: HHS interim policy (draft) |
| Compounding | BPC-157 is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA still presented it to the Pharmacy Compounding Advisory Committee on July 23, 2026: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds BPC-157 when every condition is met: a single active ingredient only (no blends or stacks), an allowed route (subcutaneous, intramuscular, oral, or topical), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. Oral forms also need documentation that the formulation is adequately absorbed by mouth in humans. The draft policy is not an FDA approval, does not add BPC-157 to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs. | TB-500 is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA's withdrawn list names it Thymosin beta-4, fragment (LKKTETQ). FDA still presented it to the Pharmacy Compounding Advisory Committee on July 23, 2026 for wound healing: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds TB-500 when every condition is met: a single active ingredient only (no blends or stacks), an allowed route (subcutaneous or intramuscular injection), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. The draft policy is not an FDA approval, does not add TB-500 to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs. |
| WADA | WADA: WADA prohibited | WADA: WADA prohibited |
| Routes | Subcutaneous injection (as sold), Oral capsule (as sold), Intraperitoneal, oral in water, and topical (animal studies) | Subcutaneous or intramuscular injection (as sold, and the routes FDA evaluated), Subcutaneous injection in horses and intraperitoneal injection in rats (TB-500 metabolism studies), Intravenous infusion, topical application, and eye drops (human trials of full-length thymosin beta-4, not TB-500) |
| Typical cost | No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient BPC-157 on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity. | No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient TB-500 on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity. |
| Last verified |
Has BPC-157 been tested directly against TB-500?
No published trial has compared BPC-157 and TB-500 directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.
What do BPC-157 and TB-500 cost?
| Dimension | BPC-157 | TB-500 |
|---|---|---|
| Typical cost | No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient BPC-157 on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity. | No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient TB-500 on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity. |
| Price detail | BPC-157 price by channel | TB-500 price by channel |
Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.
What's actually offered, what that means for you, and what to check if you're going ahead anyway: see the BPC-157 page and the TB-500 page.
Are BPC-157 and TB-500 combined?
BPC-157 and TB-500 are sold together in the premixed blends below. No study has tested the combination, and a mix is only as lawful as its least lawful ingredient. The blend pages cover what is in each product, the evidence for each ingredient, and legal status.
- GLOW: No federal basis to compound.
- KLOW: No federal basis to compound.
- Wolverine stack: No federal basis to compound.
Frequently asked questions
Which is better for tendon injuries, BPC-157 or TB-500?
Neither has been tested in a published human trial for tendon injury. BPC-157 has the more tendon specific animal data (rat Achilles transection and tendon explant studies), while TB-500 has no animal healing study of its own; the skin wound and heart data often cited for it are for full-length thymosin beta-4. Standard care for tendon injury remains load management and physical therapy. [1] [2] [5] [16]
Is there any human evidence for TB-500?
No. FDA's July 2026 briefing found no article in which TB-500 was given to humans. The trials often cited for it used full-length thymosin beta-4, which FDA says is not the same substance: a phase 2 trial of eye drops in 72 adults with dry eye did not meet its primary endpoints, though some secondary endpoints improved, and a phase 1 intravenous study in healthy volunteers found it well tolerated. [7] [15] [16]
Can a pharmacy legally compound BPC-157 and TB-500 now?
Each one separately, under conditions; the pair together, no. Neither is on the 503A bulks list, but both are covered by HHS's October 28, 2026 draft enforcement discretion policy: HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding either one as a single-ingredient product on a patient-specific prescription, by an allowed route (BPC-157: subcutaneous, intramuscular, oral, or topical; TB-500: subcutaneous or intramuscular injection), from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. Blends of BPC-157 and TB-500 are not covered. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). The policy is a draft, not an FDA approval or a 503A bulks listing, is not binding, and may be revisited; the notice was published in the Federal Register on October 30, 2026, and comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities, and state law still applies. [9] [10] [20] [21]
Are BPC-157 and TB-500 banned in sport?
Yes. BPC-157 is prohibited at all times under S0 (non-approved substances), and thymosin beta-4 and TB-500 are named under S2 of the WADA Prohibited List. [11] [12]
Is stacking BPC-157 and TB-500 supported by evidence?
No. No controlled study in animals or people has tested the two together, so claims of synergy are not supported by published data. The only published human report that used both was a retrospective knee pain survey in which 4 people received the pair, with no comparison group. Both carry a theoretical concern about promoting existing tumors: BPC-157 promotes angiogenesis in animal models, and the concern for TB-500 is carried over from thymosin beta-4, which drives cell migration and angiogenesis, and has not been tested for TB-500 itself. [2] [8] [14] [16]
Conditions studied
From the blog
- TB-500 side effects and benefits: what the evidence shows
No human study of TB-500 has been published, so its side effects in people are unknown. What FDA's 2026 review found, which studies tested a different peptide, and its legal status.
- BPC-157 before and after: reviews, results, and what controlled studies show
BPC-157 reviews and before and after stories are everywhere. Controlled results exist only in rats. What the animal healing timelines show, what the human pilots found, and why anecdotes mislead.
- BPC-157 capsules and pills: what oral BPC-157 was tested for, and what is missing
BPC-157 capsules and pills rest on rat gut, ligament, and fistula studies. No study has measured how much a capsule absorbs in people, and the two registered oral studies have posted no results.
- BPC-157 human studies: every published report and registered clinical trial
Every published BPC-157 human report, with sample size and limits, plus every registered clinical trial on ClinicalTrials.gov. About 30 people, no control groups, and no randomized results yet.
- Klow vs Glow peptide: what KPV adds and what is known
Klow is the Glow blend (GHK-Cu, BPC-157, TB-500) plus KPV. Each ingredient compared, what KPV is claimed to add, how both relate to the Wolverine stack, and why no study tests either blend.
- TB-500 vs thymosin beta-4: is it the same peptide?
FDA says TB-500 and thymosin beta-4 are not the same substance. What each one is, which one the human and animal studies used, capsules and sprays, and the cancer question.
More on the blog
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (J Appl Physiol 2011)PubMed 21030672, 2011
- [2]Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing (Cell Tissue Res 2019)PubMed 30915550, 2019
- [3]Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications (Curr Neuropharmacol 2016)PubMed 27138887, 2016
- [4]Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (Curr Pharm Des 2011)PubMed 21548867, 2011
- [5]Malinda KM et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol 1999PubMed 10469335, 1999
- [6]Bock-Marquette I et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004PubMed 15565145, 2004
- [7]Sosne G et al. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase II clinical trial. Clin Ophthalmol 2015PubMed 26056426, 2015
- [8]Goldstein AL et al. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther 2012PubMed 22074294, 2012
- [9]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [10]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, October 28). BPC-157 vs TB-500: evidence, cost, and legality. https://peptideagent.ai/compare/bpc-157-vs-tb-500- HTML link
<a href="https://peptideagent.ai/compare/bpc-157-vs-tb-500">BPC-157 vs TB-500: evidence, cost, and legality</a>, PeptideAgent, updated October 28, 2026.